Research and R&D: when literature review and patent analysis become continuous

R&D functions in research-intensive industries — pharma, biotech, materials science, semiconductors, advanced engineering — have an unusual relationship with information volume. The literature in any active field grows faster than any human can read. Patent filings happen at industrial scale. Competitor pipelines, technical disclosures, and academic conferences produce a continuous stream of information that the research team has to monitor and synthesize.

AI has gone from helpful in R&D to essential in the past three years. Literature review that used to be a quarterly exercise is now continuous. Patent landscape analysis that used to take months happens in hours. Hypothesis generation that depended on a researcher's recall now draws on the model's read of the entire field.

The bill is real. The competitive intelligence stakes are extreme. The local-SLM case for R&D is one of the strongest in any operational category we have covered.

The work

R&D AI workflows include several distinct categories.

Literature monitoring: keeping the team aware of new publications in their specific area of focus. This means processing PubMed, arXiv, and field-specific repositories at high frequency, filtering for relevance, summarizing the relevant items, and pushing the synthesis to the research team.

Patent landscape analysis: reading patent filings to understand what competitors are working on, what white space exists, what IP risks the team faces. Patent documents are long, dense, and highly structured; analysis at scale is impractical without AI.

Hypothesis generation: combining knowledge from many papers to propose research directions. A model that has read the field's literature can suggest connections a single researcher would miss.

Internal R&D documentation: drafting research summaries, internal reports, and conference presentations. Translating the team's work into the formats and tones each audience expects.

Regulatory document drafting: for pharma and medical devices specifically, drafting submissions to regulatory agencies. These documents are long, structured, and have to match very specific formats.

Each category has its own volume profile and constraints. They all share the property that the data is competitively valuable — both the inbound literature and the outbound analysis.

The math

The numbers vary by industry, but the order of magnitude is consistent for any serious R&D operation.

A representative pharma research function tracks roughly ten thousand new publications per month across its therapeutic areas of focus. Each publication needs relevance filtering and summary generation, with some receiving deeper analysis. Patent monitoring adds another several thousand documents per month. Internal R&D documentation adds tens of thousands of operations per year. Regulatory drafting is small in count but extremely high in token volume per item.

The aggregate workload is somewhere in the range of two to ten million tokens per day for the inbound monitoring and analysis, plus a similar order of magnitude for the outbound documentation. At frontier pricing, the bill is in the low to mid six figures per year for a serious mid-sized research function.

For large pharma research operations, the bill is in the seven figures per year. For research-heavy industries — pharma giants, semiconductor design houses, top-tier biotech — the literature and patent analysis bill alone can be a meaningful line item in the R&D budget.

Why this is one of the strongest local-SLM cases anywhere

The properties are all present, with several at the extreme of any operational category.

The work is unusually narrow. Each R&D function operates in a specific scientific or technical domain — a particular therapeutic area, a particular materials system, a particular technology stack. A model fine-tuned on that domain's literature and the company's own research corpus outperforms a general model dramatically.

The work is repetitive in structure but not in content. The same kinds of analyses, applied to a constantly evolving body of literature. Specialization compounds on the analytical patterns; the content evolves with the field.

The volume is enormous, and growing as the literature grows.

The privacy and competitive intelligence story is extreme. The most valuable thing an R&D function produces is its analysis — what hypotheses it is pursuing, what connections it is drawing, what gaps it is identifying. This analysis is the company's IP. Sending it to a third-party cloud LLM exposes the company's research direction in ways that compliance, IP counsel, and the chief scientific officer take seriously.

The patent analysis story is its own argument. Patent search queries and analyses reveal the company's IP strategy. Routing those through a third-party AI provider is, for many companies' IP attorneys, a posture they will not accept.

The latency story is moderate. Most R&D work is batch-oriented, but the iteration loop for a researcher exploring a hypothesis benefits from low latency.

What the fine-tuned model enables

A model fine-tuned on the company's R&D corpus enables analysis that a cloud LLM cannot.

It can read the company's internal research notes alongside the public literature. The model can connect a hypothesis a researcher proposed last year to a paper published this week, in ways no general model can do — because the general model doesn't have access to the researcher's notes.

It can recognize the company's specific terminology, internal code names, and proprietary methodologies. Patent claims that use the company's internal terminology can be classified and analyzed accurately, where a general model would treat them as unfamiliar text.

It can preserve the company's analytical lens. The way the research team thinks about a problem — what they look for, what they discount, what they weight heavily — is captured in the historical corpus and reproduced in the model's analyses.

The result is an AI research collaborator that knows the team's body of work and the field's body of work, and can connect the two with intelligence that depends on having access to both. A cloud LLM has access to the public field but not to the company's internal work. The fine-tuned local model has access to both.

What changes with local inference

An R&D workflow on a local SLM looks like this.

A model is fine-tuned on the company's R&D corpus — internal research notes, internal reports, the literature the team has historically engaged with deeply, the patents the team has filed and analyzed. The fine-tuning happens in a controlled environment that respects the IP sensitivity.

The model runs on infrastructure R&D controls. Inbound literature and patent feeds flow in. The model produces classifications, summaries, hypothesis suggestions, and analytical briefs. Internal documentation gets drafted with the model's assistance.

The R&D intelligence stays inside the company. The accumulated knowledge of what the team is working on, what hypotheses it is pursuing, and what its analytical lens is — all of this remains the company's proprietary asset.

The cost flips from per-operation to fixed. The literature can grow, the patent volume can grow, the team's work can intensify — none of it scales the bill.

When the cloud LLM is still acceptable

A narrow set of cases.

For early-stage research before the team's analytical lens has been developed enough to make fine-tuning worthwhile.

For workflows operating only on public literature without crossing into the company's internal analysis. Some pure literature monitoring can be designed this way.

For one-off projects in adjacent areas where the company doesn't have deep historical corpus to fine-tune on.

For most serious R&D work — the recurring, deep-domain, IP-sensitive analysis that constitutes the bulk of how a research function operates — the local-SLM case is overwhelming.

The pattern, at maximum strength

Avery NXR is a Next.js scaffolding tool. It is not an R&D platform. The architectural pattern repeats, at its strongest.

R&D AI is a narrow (within each scientific or technical domain), repetitive (in structure), high-volume, extreme-privacy, IP-critical workload. The cost case is real. The privacy case is extreme. The quality case — that a model trained on the team's internal corpus can do analysis no cloud LLM can — is uniquely strong in this category.

The R&D AI vendors that build excellent local-inference tools — with appropriate fine-tuning on each customer's research corpus, integration with the major literature and patent databases, and IP-friendly business models — will find willing buyers in every research-intensive company. The cloud-LLM-default products will hold the long tail and the early-stage market, but the institutional research segment is going to pivot to local infrastructure rapidly as the tools mature.

The pattern continues. R&D is one of the workflows where the local-SLM case is foundational because the IP at stake makes cloud LLMs structurally problematic, and the analytical quality improvement from fine-tuning on internal corpus is dramatic. Research organizations that move first will accelerate their work while protecting the IP that makes them valuable.